Abstract
Essential hypertension is an insulin resistant state. Early insulin signaling steps are impaired in essential hypertension and a large body of data suggests that there is a crosstalk at multiple levels between the signal transduction pathways that mediate insulin and angiotensin II actions. At the extracellular level the angiotensin converting enzyme (ACE) regulates the synthesis of angiotensin II and bradykinin that is a powerful vasodilator. At early intracellular level angiotensin II acts on JAK-2/IRS1-IRS2/PI3-kinase, JNK and ERK to phosphorylate serine residues of key elements of insulin signaling pathway therefore inhibiting signaling by the insulin receptor. On another level angiotensin II inhibits the insulin signaling inducing the regulatory protein SOCS 3. Angiotensin II acting through the AT1 receptor can inhibit insulininduced nitric oxide (NO) production by activating ERK 1/2 and JNK and enhances the activity of NADPH oxidase that leads to an increased reactive oxygen species generation. From the clinical standpoint, the inhibition of the renin angiotensin system improves insulin sensitivity and decreases the incidence of Type 2 Diabetes Mellitus (T2DM). This might represent an alternative approach to prevent type 2 diabetes in patients with hypertension and metabolic syndrome, (i.e. insulin resistant patients). This review will discuss: a) the molecular mechanisms of the crosstalk between the insulin and angiotensin II signaling systems b) the results of clinical studies employing drugs targeting the renin-angiotensin IIaldosterone systems and their role in glucose metabolism and diabetes prevention.
Keywords: Insulin, Renin-Angiotensin-Aldosterone, Glucose Metabolism, Diabetes, hypertension, angiotensin converting enzyme (ACE), renin-angiotensin Iialdosterone systems
Current Vascular Pharmacology
Title: The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Volume: 6 Issue: 4
Author(s): Giovanna Muscogiuri, Alberto O. Chavez, Amalia Gastaldelli, Lucia Perego, Devjit Tripathy, Mario J. Saad, Licio Velloso and Franco Folli
Affiliation:
Keywords: Insulin, Renin-Angiotensin-Aldosterone, Glucose Metabolism, Diabetes, hypertension, angiotensin converting enzyme (ACE), renin-angiotensin Iialdosterone systems
Abstract: Essential hypertension is an insulin resistant state. Early insulin signaling steps are impaired in essential hypertension and a large body of data suggests that there is a crosstalk at multiple levels between the signal transduction pathways that mediate insulin and angiotensin II actions. At the extracellular level the angiotensin converting enzyme (ACE) regulates the synthesis of angiotensin II and bradykinin that is a powerful vasodilator. At early intracellular level angiotensin II acts on JAK-2/IRS1-IRS2/PI3-kinase, JNK and ERK to phosphorylate serine residues of key elements of insulin signaling pathway therefore inhibiting signaling by the insulin receptor. On another level angiotensin II inhibits the insulin signaling inducing the regulatory protein SOCS 3. Angiotensin II acting through the AT1 receptor can inhibit insulininduced nitric oxide (NO) production by activating ERK 1/2 and JNK and enhances the activity of NADPH oxidase that leads to an increased reactive oxygen species generation. From the clinical standpoint, the inhibition of the renin angiotensin system improves insulin sensitivity and decreases the incidence of Type 2 Diabetes Mellitus (T2DM). This might represent an alternative approach to prevent type 2 diabetes in patients with hypertension and metabolic syndrome, (i.e. insulin resistant patients). This review will discuss: a) the molecular mechanisms of the crosstalk between the insulin and angiotensin II signaling systems b) the results of clinical studies employing drugs targeting the renin-angiotensin IIaldosterone systems and their role in glucose metabolism and diabetes prevention.
Export Options
About this article
Cite this article as:
Muscogiuri Giovanna, Chavez O. Alberto, Gastaldelli Amalia, Perego Lucia, Tripathy Devjit, Saad J. Mario, Velloso Licio and Folli Franco, The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909715
DOI https://dx.doi.org/10.2174/157016108785909715 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review)
Current Pharmaceutical Design Heteromerization as a Mechanism Modulating the Affinity of the ACE2 Receptor to the Receptor Binding Domain of SARS-CoV-2 Spike Protein
Current Proteomics Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Schizophrenia and Liver Dysfunction Caused by Portacaval Shunting
Current Psychiatry Reviews Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun
Current Pharmaceutical Design Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient
Current Pharmaceutical Design Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews Treatment of Radiation Nephropathy with ACE Inhibitors and AII Type-1 and Type-2 Receptor Antagonists
Current Pharmaceutical Design Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design New Aspects in Sustained Drug Release Formulations
Recent Patents on Drug Delivery & Formulation Primary Vesicoureteric Reflux and Reflux Nephropathy - New Insights
Current Pediatric Reviews Computational Biological Analysis Reveals a Role for Nitric Oxide Synthase and Adiponectin in the Pathobiology of Insulin Resistance Syndrome and Coronary Artery Disease
Current Nutrition & Food Science